Hennion & Walsh Asset Management Inc. Sells 56,100 Shares of Mirum Pharmaceuticals, Inc. $MIRM

Hennion & Walsh Asset Management Inc. lessened its holdings in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 59.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 37,492 shares of the company’s stock after selling 56,100 shares during the quarter. Hennion & Walsh Asset Management Inc. owned 0.06% of Mirum Pharmaceuticals worth $4,389,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Glenmede Trust Co. NA grew its stake in Mirum Pharmaceuticals by 66.9% in the first quarter. Glenmede Trust Co. NA now owns 5,532 shares of the company’s stock valued at $511,000 after acquiring an additional 2,217 shares during the period. Janus Henderson Group PLC raised its position in shares of Mirum Pharmaceuticals by 14.5% during the first quarter. Janus Henderson Group PLC now owns 6,945,813 shares of the company’s stock worth $641,764,000 after purchasing an additional 880,505 shares during the period. ADAR1 Capital Management LLC acquired a new stake in shares of Mirum Pharmaceuticals during the first quarter worth about $573,000. California State Teachers Retirement System lifted its holdings in shares of Mirum Pharmaceuticals by 22.1% during the 1st quarter. California State Teachers Retirement System now owns 44,476 shares of the company’s stock valued at $4,109,000 after purchasing an additional 8,065 shares in the last quarter. Finally, Rock Springs Capital Management LP lifted its holdings in shares of Mirum Pharmaceuticals by 6.4% during the 1st quarter. Rock Springs Capital Management LP now owns 811,294 shares of the company’s stock valued at $74,947,000 after purchasing an additional 49,000 shares in the last quarter.

Mirum Pharmaceuticals Price Performance

Shares of Mirum Pharmaceuticals stock opened at $100.65 on Monday. The firm has a market cap of $6.54 billion, a PE ratio of -6.92 and a beta of 0.52. The business’s 50 day simple moving average is $110.33 and its 200 day simple moving average is $101.86. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.74 and a current ratio of 2.86. Mirum Pharmaceuticals, Inc. has a 52-week low of $57.79 and a 52-week high of $130.00.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($1.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.32). The firm had revenue of $176.24 million for the quarter, compared to analyst estimates of $166.33 million. Mirum Pharmaceuticals had a negative return on equity of 36.28% and a negative net margin of 139.18%.The company’s revenue was up 37.9% compared to the same quarter last year. During the same period last year, the company earned ($0.12) EPS. On average, analysts predict that Mirum Pharmaceuticals, Inc. will post -4.42 earnings per share for the current fiscal year.

Key Mirum Pharmaceuticals News

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Second-quarter revenue reached $176.24 million, beating the $166.33 million consensus estimate and rising 37.9% year over year. Growth was driven by Livmarli and Mirum’s other bile-acid therapies. Management also raised its 2026 sales outlook, providing a favorable signal about demand and the company’s commercial trajectory. Mirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Analysts remain broadly constructive despite reducing their targets. TD Cowen lowered its target to $140 and retained a “buy” rating; Citizens JMP cut its target to $137 but maintained “market outperform”; and HC Wainwright reduced its target to $140 while keeping a “buy” rating. These targets imply substantial potential upside from recent trading levels.
• Neutral Sentiment: Mirum reported a quarterly loss of $1.06 per share, wider than the $0.74 consensus loss and the $0.12 loss recorded a year earlier. The loss reflects continued investment in the company’s rare-disease pipeline, but it remains a near-term valuation concern. Mirum’s Q2 Earnings Lag Estimates, Revenues Beat, 2026 View Raised
• Negative Sentiment: Citizens warned that an “unexpected” FDA request for a Phase 3 study clouds Mirum’s near-term outlook. The additional regulatory requirement could delay development or approval plans, increase spending, and weigh on investor sentiment.
• Negative Sentiment: Senior Vice President Jolanda Howe sold 1,840 shares worth approximately $193,734, reducing her direct holdings by 59.1%. The transaction was made under a pre-arranged Rule 10b5-1 plan, which lessens its signaling value, but the sale still adds a modest negative headline.

Analyst Upgrades and Downgrades

MIRM has been the subject of a number of research reports. Wall Street Zen raised Mirum Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday. Wolfe Research assumed coverage on shares of Mirum Pharmaceuticals in a research note on Tuesday, May 19th. They issued an “outperform” rating and a $145.00 price target on the stock. Robert W. Baird set a $123.00 price target on shares of Mirum Pharmaceuticals in a report on Thursday. Morgan Stanley set a $137.00 price objective on shares of Mirum Pharmaceuticals in a research report on Thursday. Finally, JPMorgan Chase & Co. raised their price objective on shares of Mirum Pharmaceuticals from $115.00 to $125.00 and gave the stock an “overweight” rating in a report on Thursday, July 2nd. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $137.33.

Insider Buying and Selling

In related news, CEO Christopher Peetz sold 30,000 shares of the firm’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $95.84, for a total value of $2,875,200.00. Following the completion of the transaction, the chief executive officer owned 194,309 shares of the company’s stock, valued at approximately $18,622,574.56. This trade represents a 13.37% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Jolanda Howe sold 2,721 shares of the business’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $120.00, for a total transaction of $326,520.00. Following the sale, the senior vice president directly owned 3,114 shares in the company, valued at $373,680. This trade represents a 46.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 67,155 shares of company stock worth $7,185,662. 8.32% of the stock is owned by insiders.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.